How can we reduce hypertension?
Supporting the Hypertension Disparities Reduction Program to improve health outcomes
Challenge
Although blood pressure control has been improving in the general community, research has not fully addressed patients in subgroups more burdened by health problems associated with uncontrolled hypertension.
Achieving control of hypertension is challenging for both clinicians and patients, particularly given the social determinants of health that may influence outcomes.
The Hypertension Disparities Reduction Program is a research partnership between the National Heart, Lung, and Blood Institute (NHLBI) and the Patient-Centered Outcomes Research Institute (PCORI) to study efforts to improve health outcomes.
Solution
Two community-based studies tested implementation strategies to help more communities manage their condition and improve hypertension control.
Each study compared blood pressure control interventions designed and implemented with input from patients and other stakeholders.
Westat supported the partnership activities as the research coordinating unit. Key responsibilities included hosting the steering committee and Data and Safety Monitoring Board (DSMB) meetings for NHLBI and PCORI.
Results
This cooperative agreement furthers the understanding of practice- and community-based interventions to address health outcomes.
Focus Areas
Clinical Research Public Health Real-World Data and EvidenceCapabilities
Partnership Engagement Technical Assistance-
Expert Interview
Safeguarding Data Privacy: Innovations at WestatOctober 2025
Protecting the privacy of people who respond to surveys and censuses is a critical responsibility in federal data collection. During the 2010 Decennial Census, the…
-
Expert Interview
Novel Strategies Transform Clinical Trials Into Future OpportunitiesOctober 2025
For the rigorous evaluation of novel medicines, clinical trials are essential to ensure safety and efficacy. However, clinical trials are experiencing turbulent times due to…
-
Expert Interview
Real-World Insights: Nirsevimab’s Protection Against RSV in InfantsSeptember 2025
Each year in the U.S., respiratory syncytial virus, commonly known as RSV, leads to approximately 58,000 to 80,000 hospitalizations among children under age 5. The…